Bio-Thera And BeiGene Partner For Bevacizumab In China
Partnered Territory Includes Hong Kong, Macau and Taiwan
Executive Summary
Bio-Thera is collaborating with BeiGene for BAT1706, a biosimilar to Avastin (bevacizumab), to develop, manufacture and commercialize the product in Greater China.
You may also be interested in...
Biomm Backs Bio-Thera’s Brazilian Bevacizumab
China’s Bio-Thera has struck a licensing deal with Biomm that will give the Brazilian company exclusive rights to market the BAT1706 bevacizumab biosimilar in its home market.
Bio-Thera Ventures Outside China With European Bevacizumab Filing
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: